These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 36281157)
21. Identification of hub genes and analysis of prognostic values in pancreatic ductal adenocarcinoma by integrated bioinformatics methods. Lu Y; Li C; Chen H; Zhong W Mol Biol Rep; 2018 Dec; 45(6):1799-1807. PubMed ID: 30173393 [TBL] [Abstract][Full Text] [Related]
22. Identification of potential core genes at single-cell level contributing to pathogenesis of pancreatic ductal adenocarcinoma through bioinformatics analysis. Du B; Su F; Wang H; Liang H; Song X; Shao Z; Wei Y Cancer Biomark; 2022; 34(1):1-12. PubMed ID: 35068444 [TBL] [Abstract][Full Text] [Related]
23. ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: an integrated bioinformatics analysis. Islam S; Kitagawa T; Baron B; Abiko Y; Chiba I; Kuramitsu Y Sci Rep; 2021 May; 11(1):10563. PubMed ID: 34007003 [TBL] [Abstract][Full Text] [Related]
24. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma. Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274 [TBL] [Abstract][Full Text] [Related]
25. The coagulation-related genes for prognosis and tumor microenvironment in pancreatic ductal adenocarcinoma. Wang D; Cui SP; Chen Q; Ren ZY; Lyu SC; Zhao X; Lang R BMC Cancer; 2023 Jun; 23(1):601. PubMed ID: 37386391 [TBL] [Abstract][Full Text] [Related]
26. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma. Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355 [TBL] [Abstract][Full Text] [Related]
27. Prognostic significance and immune infiltration of microenvironment-related signatures in pancreatic cancer. Lu Q; Zhang Y; Chen X; Gu W; Ji X; Chen Z Medicine (Baltimore); 2021 Mar; 100(12):e24957. PubMed ID: 33761652 [TBL] [Abstract][Full Text] [Related]
28. Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma. Li Y; Zhu YY; Dai GP; Wu DJ; Gao ZZ; Zhang L; Fan YH Math Biosci Eng; 2019 Nov; 17(1):910-927. PubMed ID: 31731384 [TBL] [Abstract][Full Text] [Related]
29. Neutrophils infiltrating pancreatic ductal adenocarcinoma indicate higher malignancy and worse prognosis. Wang Y; Fang T; Huang L; Wang H; Zhang L; Wang Z; Cui Y Biochem Biophys Res Commun; 2018 Jun; 501(1):313-319. PubMed ID: 29738769 [TBL] [Abstract][Full Text] [Related]
30. A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma. Zhang Y; Zhu L; Wang X Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32024063 [TBL] [Abstract][Full Text] [Related]
31. Clinicopathological and prognostic values of MET expression in pancreatic adenocarcinoma based on bioinformatics analysis. Yao Y; Zhan R; Gong C; Lv J; Lu X Medicine (Baltimore); 2023 Oct; 102(41):e34656. PubMed ID: 37832054 [TBL] [Abstract][Full Text] [Related]
32. Construction of a circRNA-miRNA-mRNA network to explore the pathogenesis and treatment of pancreatic ductal adenocarcinoma. Xiao Y J Cell Biochem; 2020 Jan; 121(1):394-406. PubMed ID: 31232492 [TBL] [Abstract][Full Text] [Related]
33. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma. Shi T; Gao G Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488 [TBL] [Abstract][Full Text] [Related]
34. Identification of key pathways and gene changes in primary pancreatic stellate cells after cross-talk with pancreatic cancer cells (BXPC-3) using bioinformatics analysis. Tang D; Wu Q; Yuan Z; Xu J; Zhang H; Jin Z; Zhang Q; Xu M; Wang Z; Dai Z; Fang H; Li Z; Lin C; Shi C; Xu M; Sun X; Wang D Neoplasma; 2019 May; 66(3):446-458. PubMed ID: 30784291 [TBL] [Abstract][Full Text] [Related]
35. Identification of significant prognostic risk markers for pancreatic ductal adenocarcinoma: a bioinformatic analysis. Zhang Z; Sun W; Zeng Z; Lu Y Acta Biochim Pol; 2022 Jun; 69(2):327-333. PubMed ID: 35675627 [TBL] [Abstract][Full Text] [Related]
36. Upregulation of ASPM, BUB1B and SPDL1 in tumor tissues predicts poor survival in patients with pancreatic ductal adenocarcinoma. Tian X; Wang N Oncol Lett; 2020 Apr; 19(4):3307-3315. PubMed ID: 32218868 [TBL] [Abstract][Full Text] [Related]
38. Identification of Candidate Therapeutic Target Genes and Profiling of Tumor-Infiltrating Immune Cells in Pancreatic Cancer via Integrated Transcriptomic Analysis. Ding W; Wang Y; Ma Y; Lin L; Li M Dis Markers; 2022; 2022():3839480. PubMed ID: 36061357 [TBL] [Abstract][Full Text] [Related]
39. SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-κB axis. Ma Q; Wu X; Wu J; Liang Z; Liu T Int J Oncol; 2017 Oct; 51(4):1104-1114. PubMed ID: 28902358 [TBL] [Abstract][Full Text] [Related]